{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:21:38Z","timestamp":1720282898846},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.diabres.2005.03.018","type":"journal-article","created":{"date-parts":[[2005,4,16]],"date-time":"2005-04-16T11:28:33Z","timestamp":1113650913000},"page":"S28-S35","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S2","title":["Cardiovascular risk: Prevention and treatment of the metabolic syndrome"],"prefix":"10.1016","volume":"68","author":[{"given":"Jaakko","family":"Tuomilehto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2005.03.018_bib1","unstructured":"World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus, Department of Noncommunicable Disease Surveillance, Geneva: World Health Organization, 1999."},{"key":"10.1016\/j.diabres.2005.03.018_bib2","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1016\/j.diabres.2005.03.018_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","article-title":"Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS)","volume":"102","author":"Festa","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2005.03.018_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0021-9150(03)00134-5","article-title":"The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey","volume":"168","author":"Ford","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2005.03.018_bib5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.diabres.2005.03.018_bib6","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2005.03.018_bib7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archinte.164.10.1066","article-title":"Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women","volume":"164","author":"Hu","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diabres.2005.03.018_bib8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.159.10.1104","article-title":"Clustering of metabolic factors and coronary heart disease","volume":"159","author":"Wilson","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diabres.2005.03.018_bib9","doi-asserted-by":"crossref","first-page":"25F","DOI":"10.1016\/S0002-9149(99)00211-8","article-title":"Hypertriglyceridemia, insulin resistance, and the metabolic syndrome","volume":"83","author":"Grundy","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.diabres.2005.03.018_bib10","doi-asserted-by":"crossref","first-page":"25C","DOI":"10.1016\/S0002-9149(03)00006-7","article-title":"Efficacy of rosuvastatin 10mg in patients with the metabolic syndrome","volume":"91","author":"Ballantyne","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.diabres.2005.03.018_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/diabetes.41.7.826","article-title":"Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels","volume":"41","author":"Pouliot","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.018_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/diabetes.52.1.172","article-title":"The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat","volume":"52","author":"Nieves","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2005.03.018_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.ijo.0801792","article-title":"The relation of body fat mass and distribution to markers of chronic inflammation","volume":"25","author":"Festa","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.diabres.2005.03.018_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/01.CIR.102.2.179","article-title":"Hypertriglyceridemic waist: a marker of the atherogenic metabolic lipid triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?","volume":"102","author":"Lemieux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2005.03.018_bib15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice","volume":"24","author":"De Backer","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.diabres.2005.03.018_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.03.018_bib17","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2337\/diacare.27.9.2135","article-title":"Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the diabetes prevention study cohort","volume":"27","author":"Ilanne-Parikka","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2005.03.018_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.03.018_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diabres.2005.03.018_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2005.03.018_bib21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2005.03.018_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"CARDS investigators, primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2005.03.018_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.diabres.2005.03.018_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.diabres.2005.03.018_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1567-5688(04)90511-4","article-title":"Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes","volume":"5","author":"Franken","year":"2004","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.diabres.2005.03.018_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1567-5688(04)90461-3","article-title":"Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects","volume":"5","author":"Berne","year":"2004","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.diabres.2005.03.018_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1567-5688(04)90462-5","article-title":"Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study","volume":"5","author":"Betteridge","year":"2004","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.diabres.2005.03.018_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2003.10.004","article-title":"Effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study, effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study","volume":"147","author":"Schuster","year":"2004","journal-title":"Am. Heart J."},{"key":"10.1016\/j.diabres.2005.03.018_bib29","doi-asserted-by":"crossref","unstructured":"S. Stender, H. Schuster, P. Barter, R. Caplan, A. Raza, D. Kallend, MERCURY I Study Group, Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial, Diabetes Obes. Metab. (2004) (Epub).","DOI":"10.1111\/j.1463-1326.2004.00450.x"},{"key":"10.1016\/j.diabres.2005.03.018_bib30","first-page":"409","article-title":"A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study","volume":"47","author":"Stalenhoef","year":"2004","journal-title":"Diabetologia"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822705000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T22:26:22Z","timestamp":1586211982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822705000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":30,"alternative-id":["S0168822705000689"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2005.03.018","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}